Formulation: A crystalline solid
Formal Name: 2-bromo-acetic acid, (6S,8aR,8bR,10aR,11R,13aR)-11-[(1R)-1,5-dimethylhexyl]-2,3,5,6,7,8,8a,8b,10,10a,11,12,13,13a-tetradecahydro-2,8a,10a-trimethyl-1,3-dioxo-4a,13b-etheno-1H,9H-benzo[c]cyclopenta[h][1,2,4]triazolo[1,2-a]cinnolin-6-yl ester
Purity: ≥95%
Formula Markup: C32H48BrN3O4
Formula Weight: 618,7
Shelf life (days): 730
CAS Number: 1817841-22-7
Notes: MeTC7 is a vitamin D receptor antagonist (IC50 = 2.9 µM in a fluorescence polarization assay).{65482} It inhibits vitamin D receptor transactivation in HEK293 cells (IC50 = 20.8 µM). It decreases the viability of OVCAR-8, OV-2008, SKOV3, Caov-3, and IGROV-1 ovarian cancer cells in a concentration-dependent manner. MeTC7 (250 nM) reduces retinoid X receptor α (RXRα) and importin-4 protein levels in OV-2008 cells. It reduces tumor growth in an SH-SY5Y neuroblastoma mouse xenograft model when administered at a dose of 10 mg/kg.